Table 1.

The correction between the expression of miR-302b, EphA2 and the clinicopathologic characteristics of patients in the training cohort.

Variable	n	EphA2				miR302b
		High	Low	P		High	Low	P
Age (years)
<60	123	89	34	0.684		54	69	0.128
≧60	103	77	26			35	68
Gender
Male	113	86	27	0.366		45	68	0.892
Female	113	80	33			44	69
Primary tumor location
Fundus and cardia	110	85	25	0.205		37	73	0.085
Distal third	116	81	35			52	64
Lauren's
Diffuse	131	94	37	0.498		47	84	0.206
Intestinal	95	72	23			42	53
Depth of invasion
T1	22	12	10	0.036		15	7	0.003
T2	55	37	18			27	28
T3	118	90	28			39	79
T4	31	27	4			8	23
Lymph node metastasis
Positive	136	110	26	0.002		43	93	0.003
Negative	90	56	34			46	44
TNM stage
I	23	10	13	<0.001		16	7	<0.001
II	52	33	19			31	21
III	67	52	15			19	48
IV	84	71	13			23	61
Lymphatic invasion
Yes	97	77	20	0.002		32	65	0.001
No	81	47	34			46	35
Venous invasion
Yes	56	43	13	0.161		22	34	0.409
No	122	81	41			56	66